Nospan

Dextromethorphan Hydrobromide

Method of action: Antitussive, Cough And Cold Preparations

Treatment option: Cough

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nospan

Property	Description
Active ingredient	Dextromethorphan Hydrobromide (DM HBr)
Form	Tablet, Syrup, Oral Solution
Pharmacological class	Antitussive (Cough Suppressant)
Common use	Symptomatic cough relief
Origin	Synthetic analog

Nospan is a medicine classified as a non-opioid cough suppressant that is principally used to provide symptomatic relief from coughing. Its therapeutic action is delivered through the single active substance, Dextromethorphan Hydrobromide (DM HBr), which acts upon the central nervous system. Dextromethorphan is categorized as an antitussive.

What Type of Medicine Is Nospan? (Classification and Identity)

Nospan belongs to the antitussive pharmacological class, designating it as a medicine that functions by inhibiting the reflex that causes a cough. It is specifically categorized as a non-narcotic medication and a single-ingredient product when used for cough relief. The substance itself is a levorphanol derivative, which structurally relates it to certain other analgesics, yet it is clearly distinguished by its primary function as a cough suppressant, a role recognized for managing non-productive coughs.

Dextromethorphan: Composition, Origin, and Form

The effective component, Dextromethorphan Hydrobromide, is a synthetic analog produced through chemical synthesis rather than being derived directly from natural sources. The medicine is designed for the oral route of administration and is commonly available as a tablet, syrup, or oral solution. As an oral medication, the DM HBr is combined with solid excipients in the tablet form or suspended within an aqueous/liquid base for liquid preparations, facilitating convenient ingestion and systemic absorption.

General Therapeutic Purpose of Nospan

The general purpose of Nospan is to reduce the intensity and frequency of persistent coughing, such as when an individual experiences a bothersome cough during a typical upper respiratory infection. This is achieved through its central action, which involves influencing the medullary cough center in the brainstem, the specific neurological site responsible for regulating the involuntary cough reflex. By raising the cough threshold, the medicine mitigates the intensity of the internal signals that trigger coughing, thereby offering reliable cough relief.

What side effects are possible with Nospan?

Possible Side Effects and Safety Information

The safety profile of Dextromethorphan Hydrobromide (DM HBr), the active ingredient in Nospan, is officially classified based on effects across specific physiological systems and frequency tiers, as documented in government regulatory labeling.

Official Adverse Reaction Scope

Adverse reactions are formally grouped into System-Organ Classes (SOCs). Common effects primarily involve the Nervous System and Gastrointestinal System. Nervous system disorders commonly listed include somnolence (drowsiness) and dizziness, which may be more noticeable at the start of treatment. Gastrointestinal disorders commonly documented are nausea, vomiting, and stomach discomfort. Hypersensitivity reactions (allergic responses) are also noted under Immune System Disorders.

Classification	Examples of Officially Listed Reactions
Common	Somnolence, Dizziness, Nausea, Vomiting
Rare	Severe hypersensitivity (e.g., Anaphylaxis)

Critical Safety Restrictions and Serious Reactions

A critical safety restriction is the strict contraindication against using Dextromethorphan concurrently with Monoamine Oxidase Inhibitors (MAOIs). This combination carries the risk of a severe adverse reaction known as Serotonin Syndrome, which is documented as a serious adverse reaction in regulatory materials.

Population-specific safety considerations are also noted. Use is often restricted or contraindicated in children under four years of age. Caution is advised for individuals with hepatic impairment, as reduced clearance of the active ingredient may increase systemic exposure and the potential for adverse effects. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Overdose and Emergency Response

The official documentation for an overdose of Dextromethorphan Hydrobromide (Nospan) outlines specific clinical signs and mandated emergency actions. Documented overdose presentations primarily involve the central nervous system (CNS) with a spectrum of effects. These range from moderate symptoms such as drowsiness, dizziness, confusion, nausea, and vomiting, to more severe neurological manifestations like agitation, hallucinations (toxic psychosis), and nystagmus (involuntary eye movements).

The most serious or life-threatening outcomes officially documented are seizures, coma, and significant respiratory depression, which can progress to an absence of breathing. Cardiovascular effects such as tachycardia (rapid heart rate) and QTc prolongation are also recognized in the regulatory profile of severe toxicity.

Government guidance explicitly mandates when urgent medical attention must be sought. For any suspected overdose, it is required to seek immediate medical attention by consulting a doctor or contacting a Poison Control Center. Urgent emergency services must be called immediately if the affected person exhibits life-threatening signs, including trouble breathing, collapse, or seizure.

Overdose management is defined by regulatory bodies as primarily symptomatic and supportive care. Specific interventions described include the administration of activated charcoal to reduce absorption and monitoring of vital signs and ECG. Population-specific notes highlight that the risk for toxic effects is heightened in individuals taking other serotonergic agents or potent CYP2D6 enzyme inhibitors, which increases the potential for Serotonin Syndrome.

Therapeutic Uses of Nospan

What Nospan Treats: Main Uses and Benefits

Dextromethorphan, the active ingredient in Nospan, is used as an antitussive (cough suppressant) for temporary relief of cough symptoms. This therapeutic area is considered relevant when short-term symptomatic assistance is needed during acute, self-limiting illnesses.

Therapeutic Scope and Benefits

This medication is generally used to help address symptom clusters characterized as a dry, irritating, or hacking cough that does not involve significant mucus production. It is applied in contexts where additional symptomatic support is needed to ease coughs related to minor throat and bronchial irritation, which may occur during a common cold or influenza. The primary indications are managing a non-productive cough, addressing symptoms that interfere with daily functioning, and offering support during acute, episodic manifestations of a viral illness. The use is relevant for easing symptoms related to physical discomfort, particularly those that create noticeable physiological strain and interfere with daily functioning.

It supports the patient during difficult episodes by easing distress. It is commonly used when symptoms become more noticeable and supportive relief is needed, as it may contribute to easing the overall symptom load during periods of heightened discomfort.

Quick Fact: Symptomatic support for Dry, Irritating Coughs

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Nospan (Dextromethorphan Hydrobromide)

The criteria for using Nospan are strictly defined by official regulatory bodies to ensure appropriate population eligibility.

Absolute Contraindications

Official labeling states that Nospan is contraindicated and must not be used by individuals who are currently taking or have stopped taking a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. The medicine is also prohibited for patients with a documented hypersensitivity to Dextromethorphan or any of its components. Furthermore, it is not approved for patients experiencing severe respiratory depression.

Population-Specific Restrictions

Population Group	Regulatory Status
Pediatric Use	Not recommended for children under six years of age. Use in children under four is generally advised against due to insufficient safety data.
Pregnancy	Restricted; use is advised only if considered clearly necessary and after medical assessment.
Lactation	Not recommended as the active substance may be excreted in breast milk.
Hepatic Impairment	Caution is required for patients with moderate to severe liver dysfunction due to the drug's metabolism.

Eligibility for adults and adolescents above the regulatory minimum age is generally established for cough relief, provided none of the stated restrictions or contraindications are present. Patients with a chronic or productive cough must also use Nospan under caution.

What should I know about interactions with other medicines?

The active ingredient in Nospan, Dextromethorphan Hydrobromide (DM HBr), has officially documented interaction patterns primarily related to metabolic pathways and pharmacodynamic effects, as detailed in government regulatory labeling.

Contraindicated Combinations and Timing Restrictions

The co-administration of Nospan with Monoamine Oxidase Inhibitors (MAOIs) is a formal contraindication in regulatory labeling due to the risk of a serious, potentially fatal Serotonin Syndrome and hypertensive crisis. A mandatory 14-day washout period is required; Dextromethorphan must not be administered within 14 days of discontinuing MAOI therapy.

Pharmacokinetic Drug Interactions

Dextromethorphan is extensively metabolized by the CYP2D6 enzyme. Concomitant use with Potent CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine, Paroxetine) is documented to reduce the clearance of Dextromethorphan. This pharmacokinetic interference results in a substantial increase in plasma exposure (elevated AUC/Cmax) of DM HBr, raising the potential for toxic effects. The interaction is classified as clinically significant by regulatory bodies.

Pharmacodynamic Effects and Substance Interactions

Co-administration with other Serotonergic Agents (such as SSRIs and SNRIs) may lead to additive effects, officially increasing the risk of Serotonin Syndrome. Furthermore, Nospan carries a restriction regarding use with Central Nervous System (CNS) depressants, including alcohol (ethanol), due to the potential for additive CNS depressant effects. Caution is also noted for individuals who are known CYP2D6 Poor Metabolizers, as they naturally exhibit higher Dextromethorphan exposure, which elevates the baseline interaction risk.

Mechanism of Action

Central Neural Suppression via NMDA and Sigma Receptors

Dextromethorphan, along with its active metabolite Dextrorphan, exerts its central activity by engaging key molecular targets within the Central Nervous System. It functions as a non-competitive antagonist of the excitatory N-methyl-D-aspartate (NMDA) receptor and an agonist of the Sigma-1 (sigma1) receptor. This dual interaction modifies the signaling sequences that normally amplify afferent neural input, resulting in decreased overall central neuronal excitability.

Elevation of the Medullary Cough Threshold

The molecular action dampens the activity of the Medullary Cough Center in the brainstem, the core integrative site for afferent input related to the defense reflex. The resulting physiological change is an elevation of the cough threshold, meaning a significantly stronger afferent signal is required to initiate the efferent (motor) command for the involuntary reflex.

Functional Constraints of the Mechanism

As a purely centralized reflex suppressant, the mechanism does not engage the peripheral processes of the respiratory tract, such as modulating inflammatory mediators or altering mucus viscosity. The suppressive action is functionally constrained where the reflex is a necessary physiological response for airway clearance.

Dosage and Administration Information

Nospan, which contains Dextromethorphan Hydrobromide, is strictly administered via the oral route in available dosage forms such as tablets, softgels, syrup, and oral suspension. The medicine is taken according to established parameters, focusing on dose limits and timing.

Standard Dosing and Frequency

For adults and adolescents 12 years of age and older, the standard single dose of the immediate-release formulation is generally 30 mg, though specific products may allow 10 to 20 mg. This dose is intended to be repeated as-needed at intervals ranging from every 4 hours to every 8 hours, depending on the strength used. The maximum intake is limited to 120 mg within any 24-hour period. For extended-release formulations, the dose is typically 60 mg administered every 12 hours.

Contextual Use Principles

Administration is not dependent on meal times; the medicine may be taken without regard to food. For liquid preparations, such as syrups or oral suspensions, the dose is measured with a calibrated dosing device supplied with the product to ensure accuracy. The overall use of Nospan is structured as a short-term intervention. Usage is typically discontinued if the cough persists for more than 7 days. Standard usage parameters include restrictions for children under 4 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nospan

Research Evidence for Acute Cough Relief (Colds and URIs)

Research exploring Nospan (Dextromethorphan HBr) in the context of temporary, acute cough—such as those associated with the common cold or upper respiratory infections (URIs)—has primarily involved short-term, controlled trials. These studies were used in research exploring how symptoms change over time, typically lasting only a few days to a week. Researchers evaluated outcomes related to physical discomfort by tracking objective measures, such as how often a patient coughed, alongside patient-reported outcomes describing perceived discomfort and severity scores.

Findings varied across the body of evidence. Some trials reported measured short-term changes in cough frequency compared to placebo, while other trials reported no significant differences. Systematic reviews summarizing the evidence have highlighted the heterogeneity (variability) of the reported results. In many acute cough studies, a significant effect was also observed in the placebo group, which can complicate the interpretation of measured differences. Research so far indicates that while Nospan was studied for symptomatic relief, the measured differences from placebo were often small and not consistently observed across all studies.

Research on the Cough Reflex Mechanism

Beyond studies conducted during periods of increased symptom activity from illness, other research has explored Dextromethorphan's effect in a controlled environment. These studies focus on the cough reflex by monitoring the Cough Reflex Sensitivity. Findings from these acute, single-dose laboratory studies documented measured changes in the cough reflex threshold. However, the results apply only to the specific, controlled conditions under which they were conducted. A direct relationship between the measured changes in the cough reflex sensitivity in the lab and the degree of clinical relief experienced by an ill patient is not fully established in the research.

Evidence in Specific Patient Populations and Research Gaps

Studies examining Nospan have typically focused on adult populations with acute cough, meaning the follow-up durations were limited. Long-term effects are not fully established because relevant data are limited. Research describing evidence in special populations is insufficient; specifically, data for children under 12 years of age remains insufficient for clinical certainty due to data limitations. The available research base contributes to the broader evidence landscape, but certainty remains low regarding consistent clinical performance in real-world settings.

Key Studies & References Dextromethorphan Drug Information - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Nospan (FAQ)

Q: How quickly does Nospan start working after you take it?

A: Official regulatory information does not typically state a precise time for the onset of action. However, the medicine is generally recognized as a short-acting product. Dosing intervals listed in the product label typically range from every 4 to 8 hours.

Q: Is it normal to feel a bit dizzy after taking Nospan?

A: Dizziness and somnolence (drowsiness) are commonly reported adverse reactions in the official safety profile. These effects are based on data from regulatory sources regarding expected side effects.

Q: Is Nospan safe for people who have kidney issues?

A: Official product information for single-ingredient Nospan often states that no dose adjustment is typically advised for patients with mild to moderate kidney impairment. However, caution is advised for patients with severe kidney disease.

Q: Does Nospan interact with common allergy medications like antihistamines?

A: Regulatory warnings exist regarding the combination of Nospan with CNS depressants. Certain allergy medications, such as older antihistamines, fall into this category. Combining these may increase the risk of side effects like extreme drowsiness, according to regulatory warnings.

Q: Can children or adolescents use Nospan safely?

A: Official labeling typically restricts use in children under 4 years of age due to limited safety data. Consultation with a healthcare professional is generally recommended before use in children under 12.

Q: Does Nospan affect liver function or require monitoring?

A: Official labeling advises caution for patients with moderate to severe hepatic impairment (liver dysfunction). This is because the drug is processed in the liver, and impairment could affect how the body clears the active ingredient.

Q: Is Nospan meant for acute pain or is it for chronic conditions?

A: According to official labeling, Nospan is indicated for the temporary relief of acute cough. It is structured as a short-term intervention and should be discontinued if the cough persists beyond about seven days.

Q: Are there specific diseases that would make Nospan unsafe to use?

A: Official warnings advise caution or contraindication for patients with severe respiratory depression or an ongoing or chronic cough. This includes coughs associated with conditions like smoking, asthma, or emphysema, or coughs that produce excessive mucus.

Q: Can Nospan be crushed or should it be swallowed whole?

A: Official dosing instructions for solid dosage forms, especially extended-release tablets or capsules, commonly state that the product must not be crushed, chewed, or broken. This helps ensure the medicine is released into the body correctly.

Q: Is Nospan considered an NSAID or something different?

A: Nospan is not an NSAID (Nonsteroidal Anti-inflammatory Drug). Official drug classification lists it as an antitussive, which is a type of medicine specifically used as a cough suppressant.

Q: Are there any known foods or drinks that interact badly with Nospan?

A: Official regulatory warnings advise against the use of alcohol (ethanol) due to the potential for additive effects that increase CNS (Central Nervous System) depression. No common foods are typically specified in core product labeling.

Q: Are there generic versions of Nospan available?

A: The active ingredient in Nospan, Dextromethorphan Hydrobromide, is widely available as an approved, over-the-counter (OTC) generic ingredient in various dosage forms.

Q: Can Nospan cause digestive upset or constipation?

A: Official lists of adverse reactions commonly include gastrointestinal effects such as nausea and vomiting. Some official documents also list constipation as a possible side effect of the medicine.

Q: Is it safe to take Nospan if you have high blood pressure?

A: Official labeling generally does not list high blood pressure as a formal contraindication for the single-ingredient product. However, professional guidance is recommended if combining it with other drugs that can affect blood pressure.

Q: What happens if you miss a dose of Nospan?

A: General instructions for some formulations advise users to skip the missed dose and take the next dose at the regularly scheduled time. Official guidance typically advises against taking a double dose to make up for a missed one.

Q: Can Nospan cause changes in vision?

A: The official side effect profiles for the active ingredient include reports of blurred vision following administration.

Q: Is Nospan considered safe during pregnancy or breastfeeding?

A: Official information states that use during pregnancy is advised only if it is clearly necessary. Use while breastfeeding is generally not recommended because the active substance may pass into breast milk.

Q: Does Nospan have any mood-altering effects or cause anxiety?

A: Regulatory warnings highlight the risk of Serotonin Syndrome when Nospan is taken with certain other drugs. This severe reaction can cause symptoms such as agitation, confusion, and other psychiatric adverse effects.

Q: Is Nospan suitable for use in elderly patients?

A: Official documents generally do not list the elderly population as specifically contraindicated for the single-ingredient product. Adult dosing is typically permitted, provided the patient does not have other contraindications like severe liver impairment.

Q: Can Nospan cause a skin rash or allergic reaction?

A: Yes, skin rash and allergic reactions are included in the official safety information for the active ingredient. Severe allergic responses (hypersensitivity) are also noted.

How should Nospan be stored and disposed of?

Storage and Disposal Requirements

Nospan (Dextromethorphan Hydrobromide) must be stored and handled according to specific regulatory requirements to ensure product quality and child safety.

Storage/Disposal Component	Official Requirement
Temperature	Store at controlled room temperature (20 C to 25 C or 68 F to 77 F). Avoid excessive heat and moisture.
Container Integrity	Keep the container tightly closed and store the medicine in its original container.
Child Safety	A critical label instruction mandates keeping Nospan out of the sight and reach of children at all times.
Disposal	Do not flush the medicine down the sink or toilet. Unused or expired product should be discarded via a drug take-back program or by mixing the medicine with an undesirable substance (e.g., used coffee grounds or cat litter), sealing the mixture, and placing it in the household trash as per FDA guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z